• We are dedicated to supporting the discovery and development of novel diagnostics and therapeutic targets that help to save lives and improve the quality of life of cancer patients. We are dedicated to supporting the discovery and development of novel diagnostics and therapeutic targets that help to save lives and improve the quality of life of cancer patients.
  • We are fuelled by tissue-based Dx test development and validation. We are fuelled by tissue-based Dx test development and validation.
  • We wish to collaborate with partners focused on cancer drug development. Let's start the Rx-Dx process early. We wish to collaborate with partners focused on cancer drug development. Let's start the Rx-Dx process early.
  • Our biomarker DISCOVERY focus is to identify biomarkers and therapeutic targets for cancer. Our biomarker DISCOVERY focus is to identify biomarkers and therapeutic targets for cancer.
  • Our biomarker DETECTION focus uses our IHC-MARK software tool and other off-the-shelf algorithms to make automated quantitation easy. Our biomarker DETECTION focus uses our IHC-MARK software tool and other off-the-shelf algorithms to make automated quantitation easy.
  • AngioTox will predict which patients are prone to cancer drug toxicity side effects AngioTox will predict which patients are prone to cancer drug toxicity side effects
  • FAST-PATH will create faster tools to diagnose Prostate Cancer FAST-PATH will create faster tools to diagnose Prostate Cancer
  • AngioPredict will predict which cancer patients will respond positively to treatment AngioPredict will predict which cancer patients will respond positively to treatment
  • RATHER targets untreatable and aggressive forms of Breast Cancer RATHER targets untreatable and aggressive forms of Breast Cancer
  • Target Melanoma will provide greater understanding of the most aggressive type of skin cancer (Melanoma) Target Melanoma will provide greater understanding of the most aggressive type of skin cancer (Melanoma)
  • APO-DECIDE will create comprehensive tools and tests to predict which patients will benefit from chemotherapy APO-DECIDE will create comprehensive tools and tests to predict which patients will benefit from chemotherapy

Partnering

OncoMark PartneringOncoMark has invested in R&D and in-licensing of IP for diagnostic assay development. We believe that Rx-Dx partnering should begin as early as possible in the development process.

Every winning partnership starts with a simple decision Click for more details »

Products

IHC-Mark and Biomarker Interpretation Workflow OncoMark has developed proprietary Prognostic & Predictive Biomarkers panels. Our research validated software IHC-Mark provides automated nuclear, cytoplasmic and membraneous IHC stain quantitation.
Another time-saving product is our Biomarker Interpretation Workflow platform. We also have a range of new assays & IP in development.

View current products
»
 

Research Projects



 

 

Subscribe to RSS FeedCompany News

August 2013 - OncoMark's SAB member, Professor John Crown takes on role with BREAST-PREDICT
Professor John Crown, a member of the OncoMark Science Advisory Board (SAB), has become co-director of BREAST-PREDICT the Irish Cancer Society Collaborative Cancer Research Centre. » read more
August 2013 - Professor William Gallagher takes up lead Principal Investigator and Director of the Irish Cancer Society Collaborative Cancer Research Centre, BREAST-PREDICT.
Professor William Gallagher, Chief Scientific Officer in OncoMark takes up the roles of lead Principal Investigator and Director of Breast-Predict in August 2013. » read more
OncoMark Researcher presents AngioTox/AngioPredict work in recent public lecture at RCSI - March 2014
Dr David Murray (seconded to OncoMark from RCSI) presents AngioTox and AngioPredict project work. » read more

Subscribe to RSS FeedIndustry News

February 2014 - OncoMark researcher presents at IACR meeting in Galway
Dr Maria Prencipe is invited to speak at the Irish Association for Cancer Research annual meeting, Galway 27th-28th February 2014 » read more
September 2013 - 16th International Conference on Medical Imaging and Computer Assisted Intervention - Nagoya, Japan
MICCAI 2013, the 16th International Conference on Medical Image Computing and Computer Assisted Intervention, was held from September 22nd to 26th, 2013 in Nagoya, Japan, organized with Scientific Council of Japan. MICCAI attracts annually world leading scientists, engineers and clinicians from a wide range of disciplines associated with medical imaging and computer assisted surgery. Dr JesuChristopher Joseph attended on behalf of OncoMark. » read more
April 2013: Colorectal cancers predicted to rise by 45% by 2020 (www.irishtimes.com)
The number of Irish people suffering from colorectal cancer is predicted to increase by 34 per cent in women and 45 per cent in men by 2020, according to a report published today by the National Cancer Registry. The report "Colorectal Cancer Incidence, Mortality, Treatment and Survival in Ireland: 1994 - 2010" found the number of male cases increased from 983 in 1994 to 1343 in 2010 and the number of female cases increased from 769 in 1994 to 955 in 2010. » read more